Showing 1–25 of 200 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Gupta N, Garg S, Vedi S, Kunimoto DY, Kumar R, et al.
Tuberculosis (TB), an infectious disease caused by Mycobacterium tuberculosis ( Mtb ), kills 5,000 people per day globally. Rapid development and spread of various multi drug-resistant strains of Mtb emphasize that an effective vaccine is still the most cost-effectives and effici…
Khalid K, Poh CL
…c resistance crisis. To address this issue, next-generation vaccines are being developed to prevent antimicrobial resistance caused by MDR bacteria. Traditional vaccine platforms, such as inactivated vaccines (IVs) and live attenuated vaccines (LAVs), were effective in preventing…
Gregor Nosan, Andreja Cerkvenik Škafar
…s to modernize TB prevention while awaiting next-generation vaccines and may serve as a guide for other low-incidence countries.
Rappuoli R, Black S, Bloom DE
Most vaccines for diseases in low- and middle-income countries fail to be developed because of weak or absent market incentives. Conquering diseases such as tuberculosis, HIV, malaria, and Ebola, as well as illnesses caused by multidrug-resistant pathogens, requires considerable …
Helen McShane
…ce strong cellular immune responses in humans using subunit vaccines. DNA vaccines induce both CD4+ and CD8+ T cells and thus offer a potential new approach to a TB vaccine. DNA vaccines encoding various antigens from M. tuberculosis have been evaluated in the murine model, and t…
Ben Morton, MD. MPH, MBChB
…us disease and the body's response and can help develop new vaccines and treatments. The purpose of this study is to set up a human challenge model using BCG to understand how the body responds to this. If our human challenge model works well it may be used to help researchers de…
Weerasuriya CK, Harris RC, McQuaid CF, Bozzani F, Ruan Y, et al.
…rough the development pipeline, how novel tuberculosis (TB) vaccines might affect rifampicin-resistant and multidrug-resistant tuberculosis (RR/MDR-TB) is unknown. We investigated the epidemiologic impact, cost-effectiveness, and budget impact of hypothetical novel prophylactic p…
Day TA, Penn-Nicholson A, Luabeya AKK, Fiore-Gartland A, Du Plessis N, et al.
Background A therapeutic vaccine that prevents recurrent tuberculosis would be a major advance in the development of shorter treatment regimens. We aimed to assess the safety and immunogenicity of the ID93 + GLA-SE vaccine at various doses and injection schedules in patients with…
Qu W, Guo Y, Xu Y, Zhang J, Wang Z, et al.
…re has been significant progress in developing tuberculosis vaccines, such as improved BCG vaccine, subunit vaccine, DNA vaccine, live attenuated vaccine and inactivated vaccine. Among these candidate vaccines, there are some promising vaccines to improve or replace BCG vaccine e…
Huimin Chen, Ye Gu, Lei Song, Lihui Si
…bacterial infections has exacerbated the need for effective vaccines to prevent these hard-to-treat pathogens. Traditional vaccine approaches have achieved tremendous successes but often fall short for pathogens like(TB), which evades host immunity through complex mechanisms, and…
Tovar M, Sanz J, Moreno Y
…s 2B and 3 of the development pipeline. The impact of these vaccines on the general population needs to be addressed using disease-transmission models, and, in a country like China, which last year ranked third in number of cases worldwide, and where the population is aging at a …
GS Shepelkova, Vasiliy Reshetnikov, VG Avdienko, DV Shevyrev, VV Yeremeev, et al.
…aimed to compare the capabilities of three variants of mRNA vaccines encoding Esat6 epitopes of stimulating adaptive immune response formation in C57BL/6 mice (ELISpot, delayed hypersensitivity, IgG titers), as well as of protecting I/St mice against M. tuberculosis infection. Ef…
Sandip Patil, Indu Singh, Indira Kumari Verma, Anil Kumar, Juhi Sharma, et al.
…ttracted the attention of scientific communities to revisit vaccines as a potential candidate against these superbugs. Although vaccines dedicated to bacterial infections are substantially reducing antibiotic use and decreasing annual healthcare expenditures for drug-resistant in…
Soleimanpour S, Yaghoubi A, Sadat Seddighinia F, Rezaee SAR
…radicate TB by 2050. Over the last few decades, 23 novel TB vaccines have entered into clinical trials, more than 13 new vaccines have reached various stages of preclinical development, and more than 50 potential candidates are in the discovery stage as next-generation vaccines. …
Faysal MA, Tanni FY, Rahman MM, Rahman MA, Chowdhury MSR, et al.
…formatics-driven approaches in developing effective subunit vaccines against bTB, providing a foundation for experimental validation and future applications in combating this pervasive zoonotic disease, bovine tuberculosis.
An Y, Ni R, Zhuang L, Yang L, Ye Z, et al.
… strains underscores the pressing need for more efficacious vaccines and treatments. This review meticulously maps out the contemporary landscape of TB vaccine development, with a focus on antigen identification, clinical trial progress, and the obstacles and future trajectories …
Mario Tovar, Joaquín Sanz, Yamir Moreno
…s 2B and 3 of the development pipeline. The impact of these vaccines on the general population needs to be addressed using disease-transmission models, and, in a country like China, which last year ranked third in number of cases worldwide, and where the population is undergoing …
Khan Z, Ualiyeva D, Amissah OB, Sapkota S, Hameed HMA, et al.
…ug-resistant (XDR) TB requires the evolution of more potent vaccines. Therefore, this research aims to generate a universal TB subunit vaccine using advanced immunoinformatics techniques. In generating a novel multiepitope subunit vaccine, we selected the conserved and experiment…
Tjip S van der Werf, MD PhD
Prospective, randomized, double-blind, multicentre, placebo-controlled clinical phase IIa trial to evaluate safety and immunogenicity of RUTI® vaccine in Multidrug-resistant Tuberculosis (MDR-TB) patients favourably responding to standard MDR-TB treatment. Time point of vaccinati…
Leung-Theung-Long S, Coupet CA, Gouanvic M, Schmitt D, Ray A, et al.
Despite the existence of the prophylactic Bacille Calmette-Guérin (BCG) vaccine, infection by Mycobacterium tuberculosis (Mtb) remains a major public health issue causing up to 1.8 million annual deaths worldwide. Increasing prevalence of Mtb strains resistant to antibiotics repr…
Gong W, Liang Y, Wu X
… multi-drug resistant (MDR) HIV strain related coinfection. Vaccines play a key role in the prevention and control of infectious diseases. Unfortunately, the only licensed preventive vaccine against TB, bacilli Calmette-Guérin (BCG), is ineffective for prevention of pulmonary TB …
Kousha A, Farajnia S, Ansarin K, Khalili M, Shariat M, et al.
Several explanations have been suggested concerning the variety in bacille Calmette-Guerin (BCG) vaccine efficacy on strains of Mycobacterium tuberculosis (Mtb). This study aimed to compare the effect of BCG vaccination history in the prevention of the occurrence of Mtb-Beijing a…
Hongmin Kim, Jong-Seok Kim, Kee Woong Kwon, Woo Sik Kim, Minchul Park, et al.
… whether the adoptive transfer of dendritic cell (DC)-based vaccines pulsed with culture filtrate antigens (CFA) of Mycobacterium tuberculosis (Mtb) could enhance BCG efficacy and support anti-TB drug therapy. **RESULTS:** In BCG-vaccinated mice, adoptive transfer of CFA-pulsed …
Shah P, Mistry J, Reche PA, Gatherer D, Flower DR
…sistant forms of M. tuberculosis, the need for effective TB vaccines becomes imperative. Currently, the only licensed TB vaccine is Bacillus Calmette-Guérin (BCG). Yet, BCG has many drawbacks limiting its efficacy and applicability. We applied advanced computational procedures to…
Eva Akurut, Yahaya Gavamukulya, Julius Mulindwa, Moses Isiagi, Ronald Galiwango, et al.
…, necessitates an urgent need for developing more effective vaccines. This study employed an in-silico approach to design a multi-epitope vaccine targeting the PE_PGRS16 protein, a conserved virulence factor found across both species, including drug-resistant strains. PE_PGRS16 w…